Invention Grant
- Patent Title: Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
-
Application No.: US17388052Application Date: 2021-07-29
-
Publication No.: US12084498B2Publication Date: 2024-09-10
- Inventor: Cécile Bonnafous , Hélène Sicard , Renaud Buffet
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: SALIWANCHIK, LLOYD & EISENSCHENK
- The original application number of the division: US14769158
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00 ; C07K16/30 ; G01N33/574
Abstract:
The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
Public/Granted literature
- US20210363248A1 COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA Public/Granted day:2021-11-25
Information query
